339P Exploring the content validity of Patient-Reported Outcome (PRO) measures to capture the patient experience of Becker muscular dystrophy (BMD)

A. Bronson,K. Mellor,N. Kilburn,C. Marshall,T. Al-zubeidi
DOI: https://doi.org/10.1016/j.nmd.2024.07.679
IF: 3.538
2024-10-04
Neuromuscular Disorders
Abstract:This qualitative study aimed to understand the lived experiences of individuals with Becker muscular dystrophy (BMD) to inform selection of patient-reported outcome (PRO) measures for use in clinical research. The content validity of the following measures was explored: Brief Pain Inventory (BPI)-Short-Form item 3, Neuro-Qol - Upper Extremity and three PROMIS-57 domains: Physical Function, Fatigue and Pain Interference. Five further PROMIS-57 domains were assessed at a topline level.31 total participants [diagnosed BMD (n=29) or caregivers (n=2)] took part in concept elicitation (n=31) and cognitive interviews (n=22) in the US. Participants were 12–17 years (n=13) or 18-55 years (n=16) and were fully ambulatory (n=12) or required walking aid/assistance sometimes (n=9) or most of the time/always (n=8). Concept elicitation interviews included open-ended questions to explore the patient experience. Thematic analysis (in ATLAS.ti) grouped concepts into domains to develop a novel conceptual model (CM). Cognitive interviews included a 'read aloud' exercise and framework analysis assessed conceptual relevance, comprehension, and interpretation. Clinically meaningful improvement thresholds were explored qualitatively. The CM consisted of three overarching domains: Signs/symptoms (including pain, muscle cramps/spasms, fatigue, and weakness; also considered salient by participants), clinical complications, and impacts (including physical, travel, lifestyle, sleep, social, emotional, work/school and relationships) and described the serious disease burden. PRO measures were well understood and consistently interpreted. Most participants considered a 1-point change in score across a PRO to represent meaningful improvement in their lives. There were no notable differences between age groups or ambulatory status. Most PRO measures (except the Neuro-Qol) were considered conceptually relevant and appropriate to capture the patient experience of BMD in clinical trials.
neurosciences,clinical neurology
What problem does this paper attempt to address?